In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer

26Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.
Get full text

Abstract

HPV vaccines available in the market are not effective against different strains of papillomavirus, therefore, there is a need to develop a new prophylactic DNA vaccine which can work against different strains of HPVs and may lead to protection of cervical cancer against new pandemic viruses. We designed a potential prophylactic DNA vaccine by using all the consensus epitopic sequences of HPVs L2 capsid protein and performed in silico cloning of multiepitopic antigenic DNA sequence in pVAX-1 vector. Immunogenicity of vaccine has been enhanced by techniques like codon optimization, engineering CpG motifs, introducing promoters and co-injection with plasmids expressing immune-stimulatory molecules. © 2009 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Gupta, S. K., Singh, A., Srivastava, M., Gupta, S. K., & Akhoon, B. A. (2009). In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer. Vaccine, 28(1), 120–131. https://doi.org/10.1016/j.vaccine.2009.09.095

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free